Collaboration will exploit Promosome’s technologies to maximize production per mRNA.

Promosome and Recopharma inked a technology license and partnership agreement under which Promosome will receive an undisclosed but reportedly significant stake in its new partner. The deal gives Swedish company Recopharma a license to Promosome’s Translation Enhancing Element (TEE) and Re-Engineering of the mRNA Primary Structure technologies to help boost the expression of its recombinant mucin-type fusion proteins.

Recopharma will receive support from Promosome to help integrate these technologies into its production cell lines and has rights to future Promosome technologies for application in the same field. As well as receiving an equity stake in Recopharma, Promosome will gain full use of all production and enhancement data generated as a result of combining the technologies.

Recopharma’s technological inroads into the development of therapeutically relevant mucin-type fusion proteins makes the partnering opportunity an obvious choice, according to Promosome’s president and CEO, John F. Manzello. “With the technology from Promosome, the probability will dramatically increase for us to achieve commercial production quantities of the mucins for our therapeutic leads,” adds Ingemar Lagerlof, CEO of LinkMed, a major shareholder in Recopharma.

The company is exploiting a core competence in the glycan structure and biosynthesis to develop and manufacture recombinant mucin-type fusion proteins. The company says its objective is to produce mucins for use in adsorption columns for antibodies as well as for the production of mucin-based tumor vaccines or adjuvants and inhibitors of microbial adhesion.

New York-based Promosome specializes in the development of services and products to enhance gene and protein expression for applications in protein production, molecular diagnostics, DNA vaccines, genomic research, and special reagents. The firm’s TEEs are designed to maximize the amount of protein produced per unit of mRNA.

Previous articleTrius Wins $29.5M Contract to Develop Antibiotics for Gram-Negative Pathogens
Next articleAdvaxis Pads Listeria Vaccine IP through New Agreement with UPenn